Hutchens & Kramer Investment Management Group’s West Pharmaceutical WST Stock Holding History

Hutchens & Kramer Investment Management Group’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-833	Closed	-$229K	–	200
2025 Q4	$229K	Hold	833	–	–	0.08%	153
2025 Q3	$219K	Buy	+833	New	+$202K	0.09%	158
2025 Q1	–	Sell	-672	Closed	-$220K	–	180
2024 Q4	$220K	Sell	672 -9	-1%	-$2.83K	0.12%	140
2024 Q3	$204K	Buy	681 +22	+3%	+$6.74K	0.11%	153
2024 Q2	$214K	Buy	659 +136	+26%	+$48.1K	0.12%	139
2024 Q1	$207K	Buy	+523	New	+$193K	0.12%	146
2023 Q4	–	Sell	-587	Closed	-$218K	–	144
2023 Q3	$218K	Sell	587 -177	-23%	-$68.5K	0.17%	102
2023 Q2	$292K	Buy	764 +4	+0.5%	+$1.43K	0.23%	85
2023 Q1	$263K	Buy	+760	New	+$222K	0.23%	92
2022 Q2	–	Sell	-512	Closed	-$214K	–	132
2022 Q1	$214K	Hold	512	–	–	0.12%	115
2021 Q4	$212K	Buy	+512	New	+$220K	0.13%	114

Other funds holding WST

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

GIM

Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Hutchens & Kramer Investment Management Group's WST Position: Q1 2026 in Review

Hutchens & Kramer Investment Management Group sold out of West Pharmaceutical (WST) in Q1 2026, closing a stake of 833 shares — an estimated $229K sold.

Hutchens & Kramer Investment Management Group first reported a position in WST in Q4 2021 and held it in 11 quarters. The position peaked at $292K in Q2 2023. 755 funds tracked by Wall St. Rank hold WST as of Q1 2026.

Hutchens & Kramer Investment Management Group reported no remaining West Pharmaceutical position as of Q1 2026 after selling out during the quarter.
Hutchens & Kramer Investment Management Group sold 833 West Pharmaceutical shares in Q1 2026, an estimated $229K.
Hutchens & Kramer Investment Management Group first reported a position in West Pharmaceutical in Q4 2021 and held it in 11 quarters.
Hutchens & Kramer Investment Management Group's West Pharmaceutical position peaked at $292K in Q2 2023.
755 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Hutchens & Kramer Investment Management Group's 13F filing for Q1 2026, filed 15 Apr 2026.